Omics-Insights: Your Weekly Genomics & Proteomics Digest

Greetings, Omics Enthusiasts!

Welcome to our latest Omics Newsletter, your portal to the freshest updates and innovations in genomics. This week's newsletter brings you the latest updates from the dynamic world of Omics. In this edition, we explore the latest developments in the field, including 10x Genomics' launch of the Xenium Prime 5K Pan-Tissue and Pathways panel for enhanced gene expression profiling, Biognosys' introduction of Spectronaut 19 at ASMS 2024, and Matter Bio securing $7 million in seed funding. Additionally, Sophia Genetics has partnered with Microsoft and Nvidia for a new whole-genome sequencing solution, and Synthego has licensed the hfCas12Max enzyme from HuidaGene Therapeutics to boost cell and gene therapy. Watchmaker Genomics and SPT Labtech are collaborating on NGS library prep automation, Bionano Genomics has raised $17.9 million in financing, and Dovetail Genomics has launched the AssemblyLink? Assay for biodiversity research, explore current Omics job openings at Kinetica, including roles in business development, sales, and marketing across various regions. For job seekers, remember to quantify your success with specific numbers and mention the products and markets where you achieved results. Highlight significant deals, revenue generated, and awards to provide concrete evidence of your capabilities.

This week's latest news in the field of Omics:

10x Genomics Launches 5,000-Plex Gene Panel for Xenium

10x Genomics has unveiled its Xenium Prime 5K Pan-Tissue and Pathways panel, significantly enhancing the capacity for gene expression profiling with up to 5,000 genes. This high-plex assay offers exceptional sensitivity, specificity, and spatial fidelity, making it a powerful tool for exploring molecular pathways, biomarkers, and cell-cell interactions across various tissues and disease types. According to Dr. Kevin Wei of Harvard Medical School, the assay's data quality is reminiscent of the revolutionary impact of single-cell RNA sequencing. With rapid turnaround times and customizable options, the Xenium Prime 5K is designed for comprehensive and efficient research. The assay, which integrates advanced multimodal cell segmentation and has been developed using extensive RNA-seq data and peer-reviewed publications, is now available for preorder and will be shipped next month.

Biognosys Launches Spectronaut 19 and Showcases Advances at ASMS 2024

Biognosys is set to launch Spectronaut 19 at the ASMS 2024 Annual Conference, introducing significant enhancements in proteomics analysis, including improved quantification and support for new workflows powered by advanced AI. This release promises deeper, faster, and more scalable DIA analysis. The company will also present TrueDiscovery? P2 Plasma Enrichment for deep plasma proteomics and TrueTarget? for high-throughput drug target screening. These technologies aim to advance biomarker discovery and drug development by offering superior performance and efficiency. The launch of Spectronaut 19 and these innovative platforms underscore Biognosys' commitment to driving excellence in proteomics research.

Startup Matter Bio Raises $7M in Seed Funding

Matter Bio, a startup focused on human longevity, has secured $7 million in seed funding led by Lifespan Vision Ventures, with contributions from QuadraScope Ventures and the National Institutes of Health. The Brooklyn-based company comprises three biotech firms: MutagenTech, Loki Therapeutics, and Spellcheck Bio, each tackling different aspects of disease and genetic research. The seed funding will support Matter Bio's efforts to develop therapies that identify and correct genetic mutations and other DNA damage associated with aging. Co-founder George Church emphasizes the importance of genomic integrity in extending health spans, highlighting the company's pioneering approach in the fight against aging.

Sophia Genetics, Nvidia & Microsoft Team Up on Whole-Genome Sequencing Application

Sophia Genetics has partnered with Microsoft and Nvidia to launch a streamlined and scalable whole-genome sequencing (WGS) solution aimed at enhancing clinical research, drug discovery, and patient care. This collaboration integrates Sophia DDM's WGS analysis capabilities with Nvidia Parabricks' data processing software, all hosted on the Microsoft Azure cloud. The solution aims to deliver rapid, data-informed decisions, potentially within a day, benefiting researchers and clinicians, particularly in the treatment of rare inherited disorders. This partnership leverages advanced technologies to provide accurate and swift genomic insights, promising to significantly impact patient care and drug development.

Synthego Licenses CRISPR Enzyme from China's HuidaGene Therapeutics

Synthego has licensed the high-fidelity Cas12 nuclease, hfCas12Max, from HuidaGene Therapeutics, granting it manufacturing and commercialization rights along with the ability to sublicense for therapeutic use. This collaboration combines Synthego's advanced CRISPR production and regulatory expertise with HuidaGene's innovative enzyme technology to enhance cell and gene therapy applications. The hfCas12Max system, which fits into a single viral vector, is expected to improve the efficiency and accessibility of CRISPR tools. This partnership marks a significant step in advancing transformative cell and gene therapies, furthering the capabilities of CRISPR-based treatments.

Watchmaker Genomics, SPT Labtech Partner to Automate NGS Library Prep

Watchmaker Genomics has partnered with SPT Labtech to automate next-generation sequencing (NGS) library preparation, integrating Watchmaker's sample prep assays with SPT Labtech's automated instruments. This collaboration includes the mRNA and DNA Library Prep Kits, which have been integrated with the Firefly liquid handler. This partnership aims to enhance the efficiency and reproducibility of NGS workflows, lowering the energy barrier for accessing gene expression information and ensuring robust performance. Both companies are focused on providing innovative solutions to streamline and scale genomic research processes.

Bionano Genomics Raises $17.9M in Debt Financing

Bionano Genomics has raised $17.9 million through a private placement involving shares of common stock and senior secured convertible debentures. The financing, facilitated by accredited investors and Canaccord Genuity as the exclusive financial adviser, allows Bionano to retire previous convertible debt and provides financial flexibility for general corporate purposes. The debentures have a maturity date of May 2026 and an interest rate of 11% per year. This new financing arrangement is expected to defer principal redemption payments and reduce near-term cash needs, thereby supporting Bionano's ongoing financial strategy.

Dovetail Genomics Launches AssemblyLink? Assay for Biodiversity Research

Dovetail Genomics has introduced the AssemblyLink? Assay, a groundbreaking tool for genomic assembly that significantly reduces the time required to generate Hi-C-like libraries to a single day. Built on Dovetail's LinkPrep? Technology, the assay delivers uniform sequence coverage and enables haplotype-resolved assemblies, making it ideal for high-throughput biodiversity research. The assay supports conservation efforts by providing faster, more accurate genome assemblies. Researchers and consortia can now achieve detailed genetic insights more efficiently, aiding in the preservation of genetic diversity amidst rapid species extinction. The AssemblyLink Assay is available for immediate use and promises to enhance genomic research productivity and quality.

Current Live Omics Roles at Kinetica:

Business Development Manager – Imaging Analysis – Mid-West

Sales Executive – NGS Software – US

Account Manager – Mid-Atlantic – Genomics reagents.

Marketing Manager – Genomics – Northern California

Business Development Manager - Synthetic Biology – West Coast

Business Development Manager - Synthetic Biology – East Coast

Sales Specialist – Spatial Biology Equipment – Boston US

Account Manager – NGS - Boston US

Job Hunting Tips from an Omics Specialist Recruiter - Quantify Your Success:

Use specific numbers to demonstrate your achievements. For instance, instead of saying "increased sales," say "increased sales by 30% in Q4 through targeted marketing campaigns and strategic partnerships." Break down your contributions in measurable terms, such as "closed 20% more deals than the previous quarter by implementing a new customer outreach strategy," or "achieved a 50% increase in customer retention by developing personalized follow-up processes." Additionally, make sure to mention the products you sold and the markets or regions where you achieved these results to provide context and relevance.

Highlight significant deals you've closed, the revenue generated, and any awards or recognitions you received for your performance. This not only provides concrete evidence of your capabilities but also shows potential employers that you can deliver tangible results. By detailing the specific products and locations of your sales achievements, you give a clearer picture of your experience and expertise in various markets and product categories

Wrapping Up Another Omics-Insights:

Thank you for embarking on a journey into the dynamic world of Omics with Kinetica! Explore the latest genomics job opportunities, stay informed with industry news, and indulge in insightful blogs at www.kinetica.co.uk. Your curiosity drives my commitment to relevant content, and I'm here to provide insights that fuel your scientific endeavors. Feel free to reach out with any questions or feedback. Wishing you ongoing inspiration and discovery in your scientific pursuits. Until next week, may your experiments yield groundbreaking results, and may your Omics journey remain as fascinating as the science itself!

?

?

?

?